317 related articles for article (PubMed ID: 25865258)
1. Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.
Livingstone E; Swann S; Lilla C; Schadendorf D; Roesch A
Exp Dermatol; 2015 Sep; 24(9):709-10. PubMed ID: 25865258
[No Abstract] [Full Text] [Related]
2. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
[TBL] [Abstract][Full Text] [Related]
3. Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.
Ferrara G; Cacitti V; Improta G; Lo Re G; Corradin MT
J Am Acad Dermatol; 2016 Oct; 75(4):e133-e135. PubMed ID: 27646754
[No Abstract] [Full Text] [Related]
4. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
5. Rapid evolution of combination therapy in melanoma.
Curti BD
N Engl J Med; 2014 Nov; 371(20):1929-30. PubMed ID: 25390744
[No Abstract] [Full Text] [Related]
6. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
7. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
Ibrahim T; Routier E; Weill A; Baz M; Robert C
Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
[No Abstract] [Full Text] [Related]
8. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Bahadoran P; Allegra M; Le Duff F; Long-Mira E; Hofman P; Giacchero D; Passeron T; Lacour JP; Ballotti R
J Clin Oncol; 2013 Jul; 31(19):e324-6. PubMed ID: 23715574
[No Abstract] [Full Text] [Related]
9. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
Erfan G; Puig S; Carrera C; Arance A; Gaba L; Victoria I; Garcia-Herrera A; Alos L; Malvehy J
Acta Derm Venereol; 2017 Feb; 97(2):258-260. PubMed ID: 27353949
[No Abstract] [Full Text] [Related]
10. Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases.
Ribero S; Marra E; Tomasini CF; Fierro MT; Bombonato C; Longo C
Br J Dermatol; 2017 Apr; 176(4):1101-1102. PubMed ID: 27515562
[No Abstract] [Full Text] [Related]
11. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
Yuan P; Ito K; Perez-Lorenzo R; Del Guzzo C; Lee JH; Shen CH; Bosenberg MW; McMahon M; Cantley LC; Zheng B
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18226-31. PubMed ID: 24145418
[TBL] [Abstract][Full Text] [Related]
12. MAP-kinase pathway up or down? Just look at the skin of your patients!
Robert C; Thomas M; Mateus C
Melanoma Res; 2014 Oct; 24(5):421-3. PubMed ID: 25185691
[No Abstract] [Full Text] [Related]
13. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
14. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
[No Abstract] [Full Text] [Related]
15. Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
Blackmon JT; Dhawan R; Terry NL; Conry RM
Melanoma Res; 2017 Apr; 27(2):159-163. PubMed ID: 28252478
[TBL] [Abstract][Full Text] [Related]
16. BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.
Roux J; Pages C; Malouf D; Basset Seguin N; Madjlessi N; Baccard M; Comte C; Archimbaud A; Battistella M; Viguier M; Mourah S; Bagot M; Lebbe C
Melanoma Res; 2015 Dec; 25(6):559-63. PubMed ID: 26397052
[TBL] [Abstract][Full Text] [Related]
17. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
Verduzco D; Flaherty KT; Smalley KS
Exp Dermatol; 2015 Sep; 24(9):657-8. PubMed ID: 26010519
[No Abstract] [Full Text] [Related]
18. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
Green JS; Norris DA; Wisell J
Br J Dermatol; 2013 Jul; 169(1):172-6. PubMed ID: 23413975
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.
Hecht M; Meier F; Zimmer L; Polat B; Loquai C; Weishaupt C; Forschner A; Gutzmer R; Utikal JS; Goldinger SM; Geier M; Hassel JC; Balermpas P; Kiecker F; Rauschenberg R; Dietrich U; Clemens P; Berking C; Grabenbauer G; Schadendorf D; Grabbe S; Schuler G; Fietkau R; Distel LV; Heinzerling L
Br J Cancer; 2018 Mar; 118(6):785-792. PubMed ID: 29438368
[TBL] [Abstract][Full Text] [Related]
20. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
